98%
921
2 minutes
20
Intraoperative ventricular tachycardia (VT) ablation targeting the epicardial substrate using three-dimensional electroanatomic mapping (EAM) was performed during left ventricular assist device (LVAD) implantation. We proved that EAM can be safely performed during LVAD implantation and that an ablation strategy based on electrophysiological information may reduce VT recurrence after LVAD implantation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199846 | PMC |
http://dx.doi.org/10.1002/joa3.13029 | DOI Listing |
Front Cardiovasc Med
August 2025
Department of Cardiovascular Surgery, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Introduction: Left ventricular assist device (LVAD) implantation is a highly effective procedure for the management of selected advanced heart failure patients, prolonging patient life and improving quality. Additional cardiac pathologies, especially valvular regurgitation or coronary heart disease, are common in LVAD recipients, whereas reports on the surgical management of heart failure combined with aortic disease are rare.
Case Presentation: We present a case of a 60-year-old patient with an aortic sinus aneurysm, aortic regurgitation, and end-stage heart failure.
J Thorac Cardiovasc Surg
September 2025
Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY. Electronic address:
Objective: Our objective was to determine the long-term outcomes of concomitant tricuspid valve procedures (TVP) during continuous-flow left ventricular assist device (LVAD) implantation.
Methods: We retrospectively reviewed patients who received HeartMate II or 3 from 2004 to 2023. Nine patients who had a previous TVP were excluded.
J Heart Lung Transplant
September 2025
Vanderbilt University Medical Center, Department of Cardiac Surgery, Nashville, TN. Electronic address:
Left ventricular assist device (LVAD) explantation is technically challenging during heart transplantation (HT) and is associated with intraoperative and postoperative blood loss. This single institution study examined the effects of partial polytetrafluoroethylene (PTFE) protective coverage during HeartMate 3 implant on perioperative blood loss during the explant-HT. We found that partial PTFE coverage of the outflow graft and chassis during HeartMate 3 implant is significantly associated with reduced intraoperative and postoperative transfusion requirements, and postoperative chest tube output.
View Article and Find Full Text PDFAm J Cardiol
August 2025
Division of Cardiovascular Diseases and Hypertension, Rutgers University - Robert Wood Johnson Medical School, 125 Paterson Street, East Tower - 8th Floor, New Brunswick, New Jersey 08901, United States. Electronic address:
The use of left ventricular assist devices (LVADs) has increased in recent years as a destination therapy. The HeartMate 3 (HM3) is currently the only commercially available LVAD for implantation in the United States. Societal guidelines for multimodality cardiac imaging evaluation of LVADs and temporary mechanical support devices were recently published and serve as a comprehensive resource for the evaluation of LVAD patients.
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Department of Cardiac Surgery and Research Group for Experimental Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
Introduction: less invasive approach (LIS) has recently become increasingly used for left ventricular assist device (LVAD) implantation. However, the impact of surgical access on pump position and clinical outcomes comparing LIS-LVAD implantation to full sternotomy (ST) has not been well discussed.
Methods: Between April 2010 and February 2021, a total of 237 consecutive patients received a LVAD, 76 (32.